[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Tg Therapeutics (TGTX)

Tg Therapeutics (TGTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Tg Therapeutics 3020 CARRINGTON MILL BLVD SUITE 475 MORRISVILLE NC 27560 USA

www.tgtherapeutics.com Employees: 399 P: 877-575-8489

Sector:

Medical

Description:

TG Therapeutics, Inc. is a biopharmaceutical company focused on the acquisition, development and commercialization of pharmaceutical products for the treatment of cancer and other underserved therapeutic needs. The Company is focused on the development of a monoclonal antibody for the treatment of various B-cell proliferative disorders including lymphoma, leukemia, and auto-immune diseases. TG Therapeutics, Inc., formerly known as Manhattan Pharmaceuticals, Inc., is based in New York.

Key Statistics

Overview:

Market Capitalization, $K 8,573,394
Enterprise Value, $K 8,739,894
Shares Outstanding, K 153,069
Float, K 139,492
% Float 91.13%
Short Interest, K 29,318
Short Float 19.15%
Days to Cover 13.62
Short Volume Ratio 0.63
% of Insider Shareholders 8.87%
% of Institutional Shareholders 58.58%

Financials:

Annual Sales, $ 616,290 K
Annual Net Income, $ 447,180 K
Last Quarter Sales, $ 240,340 K
Last Quarter Net Income, $ 7,780 K
EBIT, $ 136,330 K
EBITDA, $ 134,000 K

Growth:

1-Year Return 94.25%
3-Year Return 427.90%
5-Year Return 85.65%
5-Year Revenue Growth 410,759.97%
5-Year Earnings Growth 214.46%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.05 on 08/03/26
Next Earnings Date 11/02/26
Earnings Per Share ttm 2.79
EPS Growth vs. Prev Qtr -70.59%
EPS Growth vs. Prev Year -70.59%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-56 on 04/27/12

TGTX Ratios

Ratio
Price/Earnings ttm 19.45
Price/Earnings forward 59.20
Price/Earnings to Growth 2.33
Return-on-Equity % 73.49%
Return-on-Assets % 34.14%
Profit Margin % 72.56%
Debt/Equity 1.23
Price/Sales 13.48
Price/Cash Flow 19.37
Price/Book 13.75
Book Value/Share 3.95
Interest Coverage 5.02
60-Month Beta 1.62
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.